Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABN 401

Next Previous
Search
Drug Profile

ABN 401

Alternative Names: ABN-401

Latest Information Update: 16 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abion
  • Class Antineoplastics; Benzene derivatives; Morpholines; Piperazines; Pyrazines; Pyrazoles; Pyrimidines; Small molecules; Triazoles
  • Mechanism of Action Proto-oncogene protein c-met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Solid tumours
  • Phase I Breast cancer
  • No development reported Gastric cancer; Lung cancer

Most Recent Events

  • 03 Jan 2024 Abion completes a phase-I trial in Non-small cell lung cancer (Late-stage disease, Refractory metastatic disease) in Australia and South Korea (NCT04052971),
  • 13 Oct 2023 Efficacy and adverse event data from a phase II trial in Non-small cell lung cancer (Monotherapy, Late-stage disease, Refractory metastatic disease) released by Abion
  • 18 Aug 2023 Chemical structure information added

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top